CAR-T in Children and Immune Reconstitution
Children receiving CAR-T therapy for relapsed/refractory B-ALL require structured immune reconstitution monitoring with monthly follow-up through year 1, six-monthly through year 2, then annually through year 15, with specific attention to prolonged cytopenias, hypogammaglobulinemia, and staged vaccination protocols beginning at 3 months post-infusion 1.
Pre-CAR-T Preparation and Lymphodepletion
Timing of Treatment Discontinuation
Before CAR-T infusion, specific washout periods are mandatory 2:
- Stop ≥72 hours before: TKIs and hydroxyurea
- Stop ≥1 week before: Vincristine, 6-mercaptopurine, methotrexate ≤25 mg/m², cytarabine ≤100 mg/m², non-pegylated asparaginase
- Stop ≥2 weeks before: Clofarabine, high-dose cytarabine (>100 mg/m²), anthracyclines, cyclophosphamide, methotrexate ≥25 mg/m²
- Stop ≥4 weeks before: Pegylated asparaginase
Standard Lymphodepletion Regimen
The most common approach uses cyclophosphamide plus fludarabine 2:
- Cyclophosphamide 900 mg/m² (single dose) + fludarabine 25 mg/m² daily × 3 days
- Alternative: Cyclophosphamide 30-60 mg/kg (single dose) + fludarabine 25 mg/m² daily × 3-5 days
Immune Reconstitution Monitoring Schedule
Day +100 to 1 Year: Monthly Monitoring
Monitor monthly for 1:
- Disease remission and MRD status
- Complete blood counts with differential
- Comprehensive metabolic panels
- Immunoglobulin levels (IgG, IgA, IgM)
- Immune cell markers (CD4+ T cells, CD19/CD20+ B cells)
- CAR-T persistence markers
Years 1-2: Six-Monthly Monitoring
Continue assessing 1:
- Need for subsequent treatments including allo-HCT
- Immunological recovery status
- Infection history and severity
Years 2-15: Annual Monitoring
Long-term surveillance includes 1:
- Immunological status (immune cell markers, immunoglobulins, CAR-T persistence)
- Secondary malignancies and myeloid diseases
- Autoimmune complications
- Endocrine, reproductive, and bone health (critical in growing children)
- Neurological status (recovery from ICANS)
- Cardiovascular, respiratory, gastrointestinal health
- Vaccination status updates
Management of Prolonged Cytopenias
Recognition and Risk Factors
Delayed cytopenias occur in 58% of patients with cumulative incidence of grade 3 neutropenia (30-38%), thrombocytopenia (21-29%), and anemia (5-17%) beyond day +28 1. Risk factors include baseline cytopenias, high bone marrow disease burden, prior allo-HCT within 1 year, and severe CRS/ICANS 1.
Workup for Persistent Cytopenias
Beyond day +28, investigate 1:
- Hematinic deficiencies (iron, B12, folate)
- Myelosuppressive medications (particularly co-trimoxazole)
- Viral infections (HHV-6, parvovirus B19)
- Bone marrow biopsy to exclude recurrent disease, hemophagocytosis, or myelodysplasia
G-CSF Management
Use G-CSF for severe neutropenia (<0.5 × 10⁹/L) starting day +14 onwards, after CRS/ICANS resolution 1. Recent data show prophylactic G-CSF does not increase immunotoxicity or impair CAR-T expansion 1.
For G-CSF-refractory neutropenia (ANC <100/μL lasting >30 days) affecting 5-10% of patients 1:
- Consider autologous stem cell rescue if cells available
- Donor-derived unconditioned CD34+ selected "top-up" for post-allo-HCT patients
- Anti-inflammatory therapies (dexamethasone, erythropoietin/thrombopoietin agonists)
- Allo-HCT as last resort
Infection Prophylaxis Strategy
Antimicrobial Prophylaxis
Start from lymphodepletion conditioning until 1 year post-CAR-T AND until CD4+ count >0.2 × 10⁹/L 1:
Anti-viral (HSV/VZV):
- Acyclovir 400 mg twice daily or valacyclovir 500 mg once daily
Anti-pneumocystis:
- Co-trimoxazole 480 mg once daily or 960 mg three times weekly
- Alternatives if allergic or cytopenic: Pentamidine inhalation 300 mg monthly, dapsone 100 mg daily, or atovaquone 1500 mg daily
- Critical caveat: Delay start until ANC >0.5 × 10⁹/L in prolonged myelosuppression
Anti-fungal:
- Not routine; consider posaconazole 300 mg/day, fluconazole 200 mg/day, or micafungin 50 mg IV/day for:
- Severe neutropenia (ANC <0.5 × 10⁹/L) lasting >14 days
- Long-term or high-dose corticosteroids (>72 hours)
- Post-allo-HCT patients
Immunoglobulin Replacement
Routine IVIG is recommended in children 1. In adults, consider only for serious/recurrent infections with encapsulated organisms and hypogammaglobulinemia (<4 g/L) 1.
Vaccination Protocol
Pre-CAR-T Vaccination
Vaccinate 2 weeks before lymphodepletion when possible 1:
- Influenza vaccine (even with anticipated poor response)
- SARS-CoV-2 vaccine
Post-CAR-T Vaccination Timeline
Despite B-cell aplasia limiting serological responses, vaccination remains beneficial for T-cell-mediated immunity 1:
≥3 months post-CAR-T:
- Influenza vaccine (irrespective of immunosuppression status)
- SARS-CoV-2 vaccine (T-cell immunity preserved despite B-cell aplasia)
- Consider booster upon B-cell recovery
≥6 months post-CAR-T:
- Killed/inactivated vaccines
- Must be >2 months after immunoglobulin replacement
- Contraindicated if on concurrent immunosuppressive/cytotoxic therapy
≥1 year post-CAR-T:
- Live and non-live adjuvant vaccines
- Only when fully immune reconstituted:
- CD4+ T cells >0.2 × 10⁹/L
- CD19 or CD20+ B cells >0.2 × 10⁹/L
- No concurrent immunosuppressive therapy
- Additional contraindications: <2 years post-allo-HCT, <8 months after completing immunoglobulin replacement
B-Cell Aplasia Monitoring
B-cell aplasia serves as an indirect marker of CAR-T functional persistence 3, 4. Early B-cell recovery (BCR) within 6 months post-infusion indicates loss of CAR-T persistence and significantly increases relapse risk 3.
Management of Early B-Cell Recovery
For patients with early BCR 3:
- First-line consolidation: Allo-HCT with TBI for transplant-naïve children who can safely undergo TBI
- Alternative approaches:
- Second CAR-T infusion (feasible in subset of patients)
- Maintenance chemotherapy (emerging data show good tolerability and promising outcomes)
- TKI maintenance for Philadelphia chromosome-positive ALL (mandatory in context of either HSCT or chemotherapy)
Critical distinction: Patients with prior allo-HCT with TBI or TBI contraindications should receive maintenance chemotherapy rather than repeat transplant 3.
Common Pitfalls and Caveats
Cytokine Release Syndrome Monitoring
Continuous cardiac monitoring and telemetry should begin on infusion day and continue through peak CRS risk period 2. Frequent physical exams with CBC, comprehensive metabolic panel, coagulation studies, ferritin, and CRP are essential 2.
Graft-versus-Host Disease Risk
While generally safe post-allo-HCT, histologically confirmed GvHD has been reported in pediatric patients post-tisagenlecleucel 1. Balance immunosuppression benefits against adverse impact on CAR-T viability 1.
Secondary Malignancy Surveillance
Though rare, CAR-T-derived malignancies from insertional mutagenesis have been reported 1. This mandates 15-year follow-up as required by regulatory authorities 1.
Neurological and Pulmonary Complications
These confer increased mortality risk and require specific long-term monitoring 1. Document baseline neurological status, mood, and cognition before infusion 2.